Detail page

Knowledge Web

Person

Clemens Kratochwil (1978-)

Radiologe

Name	Clemens Kratochwil
Time	1978- (Date of birth and death)
Place	Augsburg (Geburtsort) Deutschland
Academic degree	Dr. med. (Medizinische Fakultät der Univ. Ulm)
Profession	Radiologe (characteristic profession)
Variant	Clemens Walter Kratochwil Clemens Kratowchil C. Kratochwil
Related	Universitätsklinikum Heidelberg (Radiologische Klinik) (03/2009-)
Record type	Person
GND-Identifier	134026276
Record ID	134026276
Involved in show all Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) Liver metastasis of a neuroendocrine tumor demonstrates intense uptake in PSMA-PET—but not its lymph-node metastasis and primary-tumor Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) Radioligands Targeting Fibroblast Activation Protein (FAP) Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617 Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity 18F-labeled tracers targeting fibroblast activation protein Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients 68Ga-FAPI-PET/CT in patients with various gynecological malignancies Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma Targeting of activated fibroblasts for imaging and therapy FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay Targeting of activated fibroblasts for imaging and therapy Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy Role of CT Density in PET/CT-Based Assessment of Lymphoma Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617 Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 Bedeutung und Nutzen von PSMA-Liganden beim Prostatakarzinom Stellenwert der PSMA-Liganden-Bildgebung beim Prostatakarzinom F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients Radionuklidtherapie des Prostatakarzinoms mittels PSMA-Lutetium Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617 Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Evaluation der Positronen-Emissions-Tomographie mit 18F-Fluordesoxythymidin zur Beurteilung der Tumorausbreitung und des Therapieansprechens Evaluation der Positronen-Emissions-Tomographie mit 18F-Fluordesoxythymidin : zur Beurteilung der Tumorausbreitung und des Therapieansprechens

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Clemens Kratochwil (1978-)

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer

Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Liver metastasis of a neuroendocrine tumor demonstrates intense uptake in PSMA-PET—but not its lymph-node metastasis and primary-tumor

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Radioligands Targeting Fibroblast Activation Protein (FAP)

Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

18F-labeled tracers targeting fibroblast activation protein

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

68Ga-FAPI-PET/CT in patients with various gynecological malignancies

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT

[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT

PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer

First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma

Targeting of activated fibroblasts for imaging and therapy

FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay

Targeting of activated fibroblasts for imaging and therapy

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer

Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis

Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy

Role of CT Density in PET/CT-Based Assessment of Lymphoma

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients

First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas

Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study

Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

Bedeutung und Nutzen von PSMA-Liganden beim Prostatakarzinom

Stellenwert der PSMA-Liganden-Bildgebung beim Prostatakarzinom

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

Radionuklidtherapie des Prostatakarzinoms mittels PSMA-Lutetium

Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients

18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617

Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing

Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer

68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients

A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

Evaluation der Positronen-Emissions-Tomographie mit 18F-Fluordesoxythymidin zur Beurteilung der Tumorausbreitung und des Therapieansprechens

Evaluation der Positronen-Emissions-Tomographie mit 18F-Fluordesoxythymidin : zur Beurteilung der Tumorausbreitung und des Therapieansprechens